The timely editorial from Bomback et al1 on de novo and relapsing glomerular diseases after COVID-19 vaccination noted that immunoglobulin A nephropathy (IgAN) was one of the most frequently reported glomerulonephritides in this context. However, the absolute incidence was low, with 10 reports of de novo or relapsed IgAN, including 1 from our institution.2 Vaccine trial safety data in IgAN are lacking in part because immunosuppressed patients, including those with glomerular diseases, were generally excluded.